A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 [norclozapine] in Acutely Psychotic Subjects With Schizophrenia

Next Previous
Trial Profile

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 [norclozapine] in Acutely Psychotic Subjects With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Norclozapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 25 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 16 Jun 2008 Results data have been reported in an ACADIA Pharmaceuticals media release.
    • 06 Mar 2008 The treatment phase of the trial has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top